The new public protector says she will leave the dispute over the state capture report prepared by h.
Asthmatic people can now breathe a sigh of relief because there is a "smarter" way of treating their illness.
This was the message from professors Charles Feldman, a pulmonologist at Charlotte Maxeke Academic Hospital, and Robin Green, a paediatric pulmonologist at the University of Pretoria.
They were speaking at a panel discussion on the Symbicord Maintenance and Reliever Therapy (Smart), a single-inhaler therapy which has been found to provide both maintenance and reliever therapy for asthmatics.
Asthma is an incurable respiratory disorder often characterised by difficulty in breathing.
In the conventional treatment of asthma, patients use two inhalers. Reliever medication is for treating symptoms such as when a person has tightness of the chest.
The controller treatment has to be taken in the morning and evening to treat inflammation of the patient's airways.
But the Smart provides treatment for both simultaneously.
The cost of Smart is estimated at about R300 to R500 a month.